{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T14:24:39Z","timestamp":1787840679173,"version":"build-2784847793"},"reference-count":11,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>To describe the first reported instance of an acute chorioretinal inflammatory response to cabozantinib.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Case report.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>A 54-year-old Asian male presented with blurred vision 2 weeks following the commencement of cabozantinib for metastatic renal cell carcinoma. Ophthalmic examination revealed bilateral exudative retinal detachments and choroiditis in a pattern similar to Vogt\u2013Koyanagi\u2013Harada disease. Further investigations revealed latent tuberculosis (TB), and management of this ocular adverse event was with cabozantinib cessation, high-dose oral prednisone, single-agent anti-TB therapy, and methotrexate. Return of visual function and ocular anatomy occurred within 1 month.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Modern pharmacotherapy for metastatic cancer may increase survival, but a range of ocular and systemic adverse events are frequently seen. Screening and early intervention can mitigate adverse events and treatment burden, while maximizing benefits for this disadvantaged patient group.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/joco.joco_242_23","type":"journal-article","created":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T11:06:56Z","timestamp":1729076816000},"page":"103-106","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Cabozantinib-Associated Exudative Retinal Detachment and Choroiditis: A Case Report"],"prefix":"10.4103","volume":"36","author":[{"given":"Kirk A.J.","family":"Stephenson","sequence":"first","affiliation":[{"name":"Department of Ophthalmology and Visual Sciences, University of British Columbia, Vancouver, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryon R.","family":"McKay","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology and Visual Sciences, University of British Columbia, Vancouver, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine E.","family":"Paton","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology and Visual Sciences, University of British Columbia, Vancouver, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,10,16]]},"reference":[{"key":"R1-20241018","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.oret.2021.09.008","article-title":"Alphabet soup:Clinical pearls for the retina specialist-ocular toxicity of advanced antineoplastic agents in systemic cancer care","volume":"5","author":"Villegas","year":"2021","journal-title":"Ophthalmol Retina"},{"key":"R2-20241018","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s00262-018-2260-7","article-title":"Recurrent grade 4 panuveitis with serous retinal detachment related to nivolumab treatment in a patient with metastatic renal cell carcinoma","volume":"68","author":"Wang","year":"2019","journal-title":"Cancer Immunol Immunother"},{"key":"R3-20241018","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.bulcan.2017.03.013","article-title":"Cabozantinib:Mechanism of action, efficacy and indications","volume":"104","author":"Cochin","year":"2017","journal-title":"Bull Cancer"},{"key":"R4-20241018","doi-asserted-by":"crossref","first-page":"663517","DOI":"10.3389\/fonc.2021.663517","article-title":"Tyrosine kinase inhibitor cabozantinib inhibits murine renal cancer by activating innate and adaptive immunity","volume":"11","author":"Liu","year":"2021","journal-title":"Front Oncol"},{"key":"R5-20241018","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1002\/ijc.34126","article-title":"Cabozantinib-nivolumab sequence in metastatic renal cell carcinoma:The CABIR study","volume":"151","author":"Vano","year":"2022","journal-title":"Int J Cancer"},{"key":"R6-20241018","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1200\/JCO.2017.74.7352","article-title":"Cabozantinib, a new standard of care for patients with advanced renal cell carcinoma and bone metastases?Subgroup analysis of the METEOR trial","volume":"36","author":"Escudier","year":"2018","journal-title":"J Clin Oncol"},{"key":"R7-20241018","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/S0002-9394(01)00925-4","article-title":"Revised diagnostic criteria for Vogt-Koyanagi-Harada disease:Report of an international committee on nomenclature","volume":"131","author":"Read","year":"2001","journal-title":"Am J Ophthalmol"},{"key":"R8-20241018","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1186\/s12886-020-01519-5","article-title":"Vogt-Koyanagi-Harada disease-like uveitis following nivolumab administration treated with steroid pulse therapy:A case report","volume":"20","author":"Kikuchi","year":"2020","journal-title":"BMC Ophthalmol"},{"key":"R9-20241018","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ejca.2015.11.016","article-title":"Immune-related adverse events with immune checkpoint blockade:A comprehensive review","volume":"54","author":"Michot","year":"2016","journal-title":"Eur J Cancer"},{"key":"R10-20241018","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/eye.2017.222","article-title":"Neuro-ophthalmic side effects of molecularly targeted cancer drugs","volume":"32","author":"Bhatti","year":"2018","journal-title":"Eye (Lond)"},{"key":"R11-20241018","doi-asserted-by":"crossref","first-page":"e0245492","DOI":"10.1371\/journal.pone.0245492","article-title":"Treatment burden experienced by patients with lung cancer","volume":"16","author":"El-Turk","year":"2021","journal-title":"PLoS One"}],"container-title":["Journal of Current Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/joco.joco_242_23","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:27:01Z","timestamp":1787837221000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/joco.joco_242_23"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":11,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.4103\/joco.joco_242_23","relation":{},"ISSN":["2452-2325"],"issn-type":[{"value":"2452-2325","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"2023-10-24","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-01-23","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}